# US 2015/0147749 A1 · Compositions and Methods Including Recombinant B Lymphocyte Cell Line Including an Exogenously Incorporated Nucleic Acid Expressing an Exogenous Membrane Immunoglobulin Reactive to a First Antigen and Including an Endogenous Gene Expressing an Endogenous Secreted Immunoglobulin Reactive to a Second Antigen

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147749 A1
- Document ID: US20150147749A1
- Status: Published application
- Kind: A1
- Application number: 14/549,763
- Filed: 2014-11-21
- Published: 2015-05-28
- Earliest claimed: 2011-12-22
- Assignees: Elwha LLC
- Applicants: Elwha LLC
- Inventors: Roderick A. Hyde; Wayne R. Kindsvogel
- Web page: https://patentgrep.com/patent/US20150147749A1

## CPC

- C07K 16/18: against material from animals or humans
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 40/13: B-cells
- A61K 40/24: Antigen-presenting cells [APC]
- A61K 40/4275: {Prostate specific antigen [PSA]}
- A61K 40/46: Viral antigens
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/108: Orthomyxoviridae (F), e.g. influenza virus
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- C07K 16/1271: Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
- C07K 16/3069: {Reproductive system, e.g. ovaria, uterus, testes, prostate}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- C12N 5/0635: {B lymphocytes}
- G01N 33/6854: {Immunoglobulins}
- A61K 2039/505: {comprising antibodies}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/58: Prostate
- C07K 2317/14: Specific host cells or culture conditions, e.g. components, pH or temperature
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C12N 2510/00: Genetically modified cells
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Compositions and methods are disclosed herein for producing one or more immunoglobulins in an isolated B lymphocyte cell line. An isolated cell line includes an isolated B lymphocyte cell line capable of expressing at least one exogenously incorporated membrane immunoglobulin reactive to a first antigen and at least one endogenous secreted immunoglobulin reactive to a second antigen.

## Claims

### Claim at position 1

-51. (canceled)

### Claim 52

A method for producing at least one immunoglobulin in an isolated cell line comprising:
introducing into at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one first antigen to produce at least one first isolated B lymphocyte cell line;
selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one first antigen;
introducing into the at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one second antigen to produce at least one isolated recombinant B lymphocyte cell line; and
selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one second antigen.

### Claim 53 (depends on 52)

The method of claim 52 comprising:
selecting the at least one isolated recombinant B lymphocyte cell line expressing the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen.

### Claim 54 (depends on 52)

The method of claim 52 comprising:
administering the at least one first antigen to stimulate the at least one isolated recombinant B lymphocyte cell line; and
testing for the presence of the one or more secreted immunoglobulins reactive to the at least one second antigen in the at least one isolated recombinant B lymphocyte cell line.

### Claim 55 (depends on 52)

The method of claim 52 comprising:
introducing into the at least one first isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to the at least one second antigen.

### Claim 56 (depends on 52)

The method of claim 52 comprising:
introducing into the at least one isolated recombinant B lymphocyte cell line at least one exogenous nucleic acid sequence encoding one or more secreted immunoglobulins reactive to at least one third antigen to produce at least one isolated second recombinant B lymphocyte cell line;
selecting the at least one isolated second recombinant B lymphocyte cell line expressing the at least one secreted immunoglobulin reactive to the at least one second antigen and the at least one secreted immunoglobulin reactive to the at least one third antigen.

### Claim 57 (depends on 56)

The method of claim 56 comprising:
administering the at least one first antigen to stimulate the at least one isolated second recombinant B lymphocyte cell line; and
testing for the presence of the at least one exogenous secreted immunoglobulin reactive to the at least one third antigen in the recombinant B lymphocyte cell line.

### Claim 58 (depends on 52)

The method of claim 52, wherein introducing into the at least one isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen comprises introducing at least one exogenous membrane immunoglobulin reactive to the at least one first antigen.

### Claim 59 (depends on 52)

The method of claim 52, wherein introducing into the at least one isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one first antigen comprises introducing an exogenous nucleic acid encoding at least one membrane immunoglobulin reactive to the at least one first antigen.

### Claim 60 (depends on 55)

The method of claim 55, wherein introducing into the at least one first isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one second antigen comprises introducing at least one exogenous membrane immunoglobulin polypeptide reactive to the at least one second antigen.

### Claim 61 (depends on 55)

The method of claim 55, wherein introducing into the at least one first isolated B lymphocyte cell line the at least one exogenous membrane immunoglobulin reactive to the at least one second antigen comprises introducing at least one exogenous nucleic acid encoding at least one membrane immunoglobulin reactive to the at least one second antigen.

### Claim 62 (depends on 52)

The method of claim 52 comprising:
exposing the at least one isolated recombinant B lymphocyte cell line to the at least one first antigen, and
testing for the activation of the at least one isolated recombinant B lymphocyte cell line to express the exogenous secreted immunoglobulin reactive to the at least one second antigen.

### Claim 63 (depends on 62)

The method of claim 62 comprising:
isolating the exogenous secreted immunoglobulin reactive to the at least one second antigen from the at least one isolated recombinant B lymphocyte cell line or from a culture of the at least one isolated recombinant B lymphocyte cell line.

### Claim 64 (depends on 52)

The method of claim 52, wherein activating the at least one exogenously incorporated membrane immunoglobulin with the first antigen is capable of controlling expression of the at least one exogenously incorporated nucleic acid encoding at least one secreted immunoglobulin reactive to the second antigen.

### Claim 65 (depends on 52)

The method of claim 52, wherein
the at least one isolated B lymphocyte cell line comprises at least one of naïve B lymphocytes, immature B lymphocytes, transitional B lymphocytes, mature B lymphocytes, follicular B lymphocytes, memory B lymphocytes, plasmablasts, or plasma cells.

### Claim 66 (depends on 52)

The method of claim 52, wherein
the at least one isolated B lymphocyte cell line comprises at least one memory B lymphocyte.

### Claim at position 17

-79. (canceled)

### Claim 80

A method for producing at least one immunoglobulin in an isolated cell line comprising:
introducing into at least one first isolated B lymphocyte cell line at least one exogenous nucleic acid encoding one or more secreted immunoglobulins reactive to at least one first antigen to produce at least one isolated recombinant B lymphocyte cell line;
selecting the at least one isolated recombinant B lymphocyte cell line expressing the one or more secreted immunoglobulin reactive to the at least one first antigen;
introducing into the at least one isolated B lymphocyte cell line at least one exogenous membrane immunoglobulin reactive to at least one second antigen to produce at least one first isolated B lymphocyte cell line; and
selecting the at least one first isolated B lymphocyte cell line expressing the membrane immunoglobulin reactive to the at least one second antigen.

### Claim 81

(canceled)
